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Background: Direct access ﬂow measurements are considered the most useful
surveillance method for signiﬁcant stenosis, and ultrasound dilution has become
the most popular and validated technique. The goal of this study was to evaluate
access ﬂow (Qa) at the time of ﬁrst cannulation and its relationship to the survival
of vascular access in Korean hemodialysis patients.
Methods: We conducted a prospective observational study from May 2004 to June
2011. We enrolled 60 patients (36 men) who underwent the ﬁrst access operation
between January 2004 and December 2005 and were followed-up for surveillance.
Results: Maturation failure occurred in nine patients (15%). Mean time to ﬁrst use
was 1.871.2 months after surgery. The patients were followed-up for a mean of
50.5725.9 months. There were 25 deaths and six kidney transplants in patients
with a functioning access. The total percutaneous transluminal angioplasty
incidence was 50 in 27 patients (0.14/access-year). The initial Qa was
757.57476.4 mL/minute. First cannulation time was not signiﬁcantly correlated
with initial Qa (r¼0.234, P¼0.075). A total of 22 of the 60 patients (36.7%) had an
initial Qao500 mL/minute. Maturation failure, initial Qao500 mL/minute, and
the use of antiplatelet agents were risk factors for poor primary patency. Diabetic
status and use of a graft were risk factors for low cumulative patency.
Conclusion: An initial Qao500 mL/minute is a risk factor for poor primary
patency, while an initial Qao500 mL/minute is not a risk factor for low cumulative
patency or mortality.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).rean Society of Nephrology. P
ses/by-nc-nd/4.0/).
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Vascular access dysfunction in hemodialysis is associated
with a signiﬁcant increase in morbidity and cost. Access with a
blood ﬂow of 600–1000 mL/minute is necessary to allow
sufﬁcient removal of uremic toxins from a patient within a
reasonable time [1]. Routine surveillance to detect stenosis is
recommended to allow preemptive intervention before throm-
botic occlusion. Because the physiologic effect of stenosis isublished by Elsevier. This is an open access article under the CC BY-NC-
Table 1. Clinical characteristics of the study patients (n¼60)
Clinical characteristic Number (%)
Age (y) 54.9715.6
Sex, M:F (no.) 36:24
Height (cm) 163.378.7
Weight (kg) 58.4711.9
Cause of end-stage renal disease
Diabetes mellitus 27 (45.0)
Hypertension 14 (23.3)
Glomerulonephritis 1 (1.7)
Unknown 15 (25.0)
Others 3 (5.0)
Diabetes mellitus 30 (50)
Hypertension 47 (78.3)
Anticoagulation agents 39 (65.0)
Table 2. The characteristics of arteriovenous ﬁstulae
Characteristic Number (%)
Access type
Native 48 (81.4)
Graft 12 (18.6)
Access position
Left 55 (91.7)
Right 5 (8.3)
Access vessel
Radiocephalic 47 (80.0)
Brachiocephalic 1 (1.7)
Upper graft 1 (1.7)
Forearm graft 11 (16.6)
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ments are considered the most useful surveillance method to
detect stenosis, and ultrasound dilution has become the most
popular and validated technique [2]. However, the outcomes
and surveillance methods of hemodialysis access in Korean
patients remain undeﬁned. Our goal in this study was to
evaluate Qa at the time of ﬁrst cannulation and its relationship
to outcomes of vascular access in Korean hemodialysis patients.
Methods
We conducted a prospective, observational study in a hospi-
tal hemodialysis center from May 2004 to June 2011. This study
was approved by the Institutional Review Board of our Hospital
(SCHBC-IRB-09-65). Patient criteria for enrollment in the study
were as follows: (1) the ﬁrst operation for arteriovenous ﬁstula
(AVF) or arteriovenous graft (AVG) was performed at our
hospital between January 2004 and December 2005; (2) cannu-
lation was started and hemodialysis was maintained for at least
1 month; (3) Qa was measured monthly; and (4) follow-up for
access surveillance occurred at our hospital, even for patients
transferred to and receiving hemodialysis elsewhere. The type of
AVF or AVG was determined based on the preferences of two
surgeons.
Cannulation of the AVF/AVG was attempted after a clinical
assessment suggested that the access was sufﬁciently well
developed to support hemodialysis after a minimum maturation
period of 30 days. Qa was measured monthly using a Transonic
hemodialysis monitor (Transonic Systems, Inc., Ithaca, NY, USA).
All measurements were performed at a ﬁxed dialyzer blood ﬂow
of 200–250mL/minute within the ﬁrst hour after the start of
hemodialysis. Ultraﬁltration was turned off during the actual
blood ﬂow measurement. Patients in whom the AVF Qa
decreased to o500mL/minute or dropped by more than 25%,
or those in whom the AVG Qa decreased to o600mL/minute or
dropped by more than 25%, were sent for ﬁstulography.
We deﬁned ﬁrst cannulation time as the time from the
access surgery to ﬁrst cannulation. We considered the inabil-
ity to use an AVF/AVG beyond 30 days after surgery to be a
maturation failure. When maturation failure of an AVF/AVG
was suspected, the patient was referred to the surgeons who
made the access. Because surgeons rather than intervention
radiologists performed the percutaneous transluminal angio-
plasty (PTA) in contrast to the practice in most other hospi-
tals, the surgeons decided whether PTA or a revision
operation was more appropriate. PTA was performed using
standard techniques. An access stenosis was considered
hemodynamically relevant when it averaged 450% of the
luminal diameter. A balloon catheter was inﬂated in the
stenotic lesion, and patency was visualized thereafter by
additional ﬁstulography. Residual stenosis ofo30% of the
luminal diameter was considered procedural success. The
initial Qa was measured between the ﬁrst and third cannula-
tion of AVF/AVG. If maturation failure of an AVF/AVG was
suspected, then the initial Qa was measured after interven-
tion. Primary patency was deﬁned as the time elapsed from
access surgery to the time of any intervention. Cumulative
(secondary) patency was deﬁned as the time from access
surgery to complete failure of the ﬁstula or graft.
Data are presented as means7standard deviation, with 95%
conﬁdence intervals (CIs) where appropriate. The Chi-square and
Fisher’s exact tests were used to compare dichotomous variables.
Normally distributed continuous variables were compared usingStudent’s t-test. Variables inﬂuencing access patency and patient
survival were evaluated by Cox regression analysis. Values of
Po0.05 were considered to indicate statistical signiﬁcance. All
statistical analyses were performed using SPSS version 14.0 (SPSS,
Inc., Chicago, IL, USA).Results
Patient characteristics
Table 1 lists the characteristics of the 60 participants enrolled
in this study. The mean patient age was 54.9715.6 years, and
78% of the patients had hypertension. The numbers of male and
female patients were 36 and 24, respectively. The most common
cause of end-stage renal disease was diabetes mellitus (DM, 45%).
The access characteristics are shown in Table 2. Proportions of
native and left access were higher than those of graft and right
access. Radiocephalic AVF was the most common access type.
Maturation failure
Mean time to ﬁrst use of the AVF/AVG was 1.871.2 (range,
1–6) months after access surgery. Maturation failure occurred
in nine patients (15%), four of who had received AVG. Three
patients underwent revision operations. Another six AVF/AVG
patients demonstrated stenosis upon ﬁstulography but had
functional access after PTA at 1.870.7 months. The initial
mean Qa of this group was 7007230 mL/minute. Three of the
six patients lost access patency again at 3, 24, or 27 months
after the initial surgery. Two of these three patients under-
went an additional procedure.
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Patients were followed-up for a mean of 50.5725.9 months
(range, 1–89 months), for a total of 3,029 patient-months. There
were 25 deaths and six kidney transplants in patients with a
functioning access. The total PTA incidence was 50 in 27
patients (1.65 per 100 patient-months or 0.14/access-year).
The primary patency rates of AVF at 12, 24, and 36 months
were 80.0%, 57.3%, and 42.8%, respectively. The primary patency
rates for AVG at 12, 24, and 36 months were 46.9%, 37.5%, and
18.8%, respectively. There was no statistically signiﬁcant
difference in primary patency rates between AVF and AVG
(P¼0.184). The cumulative patency rate of AVF at 12 and 24
months were 89.9% and 86.6%, respectively, whereas those of
AVG at 12 and 24 months were 55.6% and 27.4%, respectively.
The cumulative patency rate of AVF was superior to those of
AVG (P¼0.000). Patient survival rates at 12, 24, and 36 months
were 83%, 68.8%, and 62.5%, respectively.
Initial Qa
The initial Qa was 757.57476.4 (range, 120–2930) mL/
minute at 1.871.2 (range, 1–6) months. Known variables,
including patient age, sex, DM, hypertension, antiplatelet
agents, and access type, did not inﬂuence the initial Qa. First
cannulation time was not signiﬁcantly correlated with initial
Qa (r¼0.234, P¼0.075). Twenty-two of 60 patients (36.7%)
had an initial Qao500 mL/minute.
Prognostic factors for access patency and patient survival
Univariate and multivariate Cox regression models revealed
predictors for access patency and survival. Patients treated
with antiplatelet agents had ﬁve times higher risk than other
patients for losing access patency. Maturation failure and an
initial Qao500 mL/minute were risk factors for poor primary
patency (Table 3, Fig. 1). Diabetic status and use of a graft were
risk factors for low cumulative patency (Table 4). An initial
Qao500 mL/minute was not a risk factor for low cumulative
patency (Table 4, Fig. 2) or mortality (Table 5, Fig. 3).Figure 1. Primary access patency in patients with an initial Qa 4500
ml/minute and those with an initial Qa o500 ml/minutes (N¼60).Discussion
The National Kidney Foundation’s Kidney Disease Out-
comes Quality Initiative (K/DOQI) guidelines recommend
routine surveillance for hemodynamically signiﬁcant stenosis
in AVGs and AVFs because prophylactic stenosis correctionTable 3. Predictors of primary access patency by univariate and multi
Parameter Univariate analysis
Relative risk 95% CI
Age (y) 1.007 0.987–1.028
Male sex 0.790 0.393–1.591
DM 0.893 0.446–1.789
HTN 1.284 0.554–2.973
AntiPLT 1.914 0.857–4.272
Maturation failure 5.641 2.555–12.454
Graft 1.719 0.765–3.859
First cannulation time 0.938 0.708–1.242
Initial Qao500 mL/min 2.042 1.013–4.119
AntiPLT, antiplatelet agent; CI, conﬁdence interval; DM, diabetes mellitus;improves access patency rates [1]. However, this approach
has been criticized as being premature, given the several
unresolved issues surrounding the predictive accuracy of the
monitoring tools. The full risks, beneﬁts, and costs of surveil-
lance programs remain unclear, as does the optimal timing of
corrective intervention; there are few methodologically ade-
quate studies that have addressed these issues [2]. Most
studies to diagnose stenosis and predict thrombosis in AVF
have been biased by small sample sizes and the reporting of
cumulative data for AVFs and AVGs, and these studies have
proposed a wide variety of diagnostic criteria [3–6]. We
introduced Qa measurements and initiated surveillance using
Transonic hemodialysis monitoring in 2004 [7]. Only a few
authors have reported access outcomes, including patency
rates and maturation failure rates, in Korean patients, and
these have been determined using a variety of methods
[8–12]. Therefore, we evaluated initial ﬂow, surveillance,
and survival of hemodialysis access in Korean patients.
In our study, the mean time to ﬁrst cannulation was
1.871.2 (range, 1–6) months. However, 25 of the 60 patients
(41.7%) were not assessed at this ﬁrst time point (data not
shown). Contrary to our expectations, the initial Qa did not
differ based on patient age, sex, DM, hypertension, anti-platelet
agents, or use of a graft. Only the ﬁrst cannulation time
inﬂuenced the initial Qa, despite not signiﬁcantly (r¼0.234,variate cox analysis
Multivariate analysis
P Relative risk 95% CI P
0.498 1.007 0.984–1.030 0.559
0.510 1.150 0.482–2.744 0.752
0.749 0.715 0.309–1.653 0.433
0.560 0.536 0.194–1.483 0.230
0.113 5.677 1.841–17.502 0.003
0.000 14.662 4.505–47.719 0.000
0.189 2.041 0.703–5.924 0.189
0.655 1.012 0.743–1.376 0.942
0.046 2.784 1.091–7.100 0.032
HTN, hypertension; Qa, access ﬂow.
Table 4. Predictors of secondary access patency by univariate and multivariate cox analysis
Parameter Univariate analysis Multivariate analysis
Relative risk 95% CI P Relative risk 95% CI P
Age (y) 1.012 0.980–1.044 0.483 1.024 0.985–1.065 0.251
Male sex 0.255 0.088–0.779 0.012 2.219 0.554–8.885 0.210
DM 3.287 1.048–10.309 0.041 13.734 2.265–83.273 0.004
HTN 0.663 0.187–2.355 0.525 1.152 0.245–5.413 0.858
AntiPLT 1.134 0.387–3.323 0.819 2.0273 0.480–8.564 0.336
Maturation failure 2.896 0.918–9.139 0.070 1.643 0.217–12.474 0.631
Graft 5.442 1.852–15.995 0.002 5.584 1.186–26.288 0.030
PTA 1.233 0.923–1.648 0.156 1.405 0.491–5.628 0.223
First cannulation time 0.868 0.574–1.313 0.502 0.730 0.434–1.228 0.236
Initial Qao500 mL/min 1.565 0.579–4.231 0.377 1.152 0.245–5.413 0.858
AntiPLT, anti-platelet agent; DM, diabetes mellitus; HTN, hypertension; PTA, percutaneous transluminal angioplasty; Qa, access ﬂow.
Figure 2. Secondary access patency in patients with an initial Qa 4500
ml/minute and those with an initial Qa o500 ml/minutes (N¼60).
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60 patients, there was no difference in the AVF/AVG ratio
among patients with a Qao500 mL/minute or among those
with a Qa Z 500 mL/minute. These results are largely con-
sistent with the report of Tonelli and colleagues [13]. These
authors showed that Qa was not inﬂuenced by patient age,
systolic blood pressure, overweight status, or diabetic status,
but was independently associated with sex and with recent
ﬁstula creation. Qa values did not change during the present
study, except during the development of access events such as
thrombosis or stenosis. Patients who experienced PTA had
signiﬁcantly lower initial Qa values than those who did
not (562.67276.9 vs. 926.27539.7 mL/minute; P¼0.002).
Although not presented here, a correlation between monthly
Qa values (Pearson’s correlation ratio, 0.704–0.841) was inde-
pendently demonstrated in both PTA and non-PTA groups. An
initial Qao500 mL/minute was a risk factor for poor primary
patency. But, an initial Qao500 mL/minute was not a risk
factor for low cumulative patency (Tables 3 and 4, Figs. 1 and
2). In addition, the results shown in Table 5 and Fig. 3 indicate
that an initial Qao500 mL/minute was not a risk factor for
mortality. These results are compatible with a previous study
in Korean patients that reported that low early access ﬂow
was associated with new vascular access events [14].The maturation failure rate of AVFs was less than that of
AVGs (10.4 vs. 33.3%, respectively), but the difference was not
signiﬁcant (P¼0.069). The AVF maturation failure rate in our
study differed from the previously reported primary failure
rates of 20%–50% [15]. The AVF/AVG ratio in our study is
consistent with that reported by Jung and colleauges [11].
They reported a primary failure rate of 13.2%, which was
similar between 142 patients with AVF and 40 patients with
AVG. The total number of PTAs with AVG was approximately
twofold the number of PTAs with AVF (1.372.0 vs. 0.771.0,
P¼0.127). Therefore, graft use is a risk factor that affects
cumulative patency (Table 4). These results are consistent
with the recent report of Lee and colleagues [17].
Song and coauthors [12] reported cumulative AVF patency
rates of 91% and 89% at 12 and 24 months, respectively, for
134 Korean patients. Because the K/DOQI guidelines recom-
mend the use of life table survival for cumulative patency
rates, we reanalyzed the primary patency rates; the recalcu-
lated rates for AVF were 87%, 77%, and 73% at 12, 24, and 36
months, respectively, and those for AVG were 55% and 33% at
12 and 36 months, respectively. The cumulative patency of
AVG was inferior to the K/DOQI guidelines, which specify that
graft cumulative patency targets of 70% at 1 year, 50% at
2 years, and 50% at 3 years should be achievable [1].
The Cox multivariate regression results shown in Table 3
indicate that the use of antiplatelet agents is a risk factor of
poor primary patency, in contrast to the Cox univariate
regression results. It is not clear why this should be the case.
However, patients using the anti-platelet agents were older
(57.3716.0 vs. 50.4714.1, P¼0.092), more likely to be
diabetic (56% vs. 32%, P¼0.176) and to have undergone more
PTA procedures (1.071.3 vs. 0.571.2, P¼0.109) than
patients who were not taking anti-platelet agents, which
could have contributed to this ﬁnding. Nevertheless, none of
these comparisons reached statistical signiﬁcance.
In the present study, the cumulative patency rates were not
associated with female sex, age older than 65 years, or diabetic
status, in contrast to previous Korean reports. Many previous
studies have reported more vascular complications in women
than in men and have suggested that gender differences in
vessel diameter may explain the poorer outcomes of ﬁstulae in
women [18–20]. In addition, the presence of DM and hyperten-
sion inﬂuence primary patency. Tonelli and colleagues [13] and
Miller and coauthors [21] found no effect of gender. Dixon and
others [18] suggested that only the type of access and the
surgeon were the risk factors, and that age, sex, race, DM, and
hypertension did not inﬂuence primary access patency.
Table 5. Predictors of decreased patient survival by univariate and multivariate cox analysis
Parameter Univariate analysis Multivariate analysis
Relative risk 95% CI P Relative risk 95% CI P
Age (y) 1.033 1.004–1.033 0.027 1.031 0.996–1.066 0.083
Male sex 1.650 0.671–4.057 0.275 1.507 0.552–4.110 0.424
DM 1.983 0.831–4.730 0.123 2.316 0.869–6.173 0.093
HTN 0.906 0.333–2.462 0.847 0.613 0.205–1.830 0.380
AntiPLT 1.411 0.552–3.608 0.522 0.918 0.311–2.706 0.876
Maturation failure 1.281 0.433–3.787 0.957 2.723 0.707–10.491 0.145
Graft 0.786 0.265–2.327 0.663 1.192 0.309–4.590 0.799
PTA 0.975 0.727–1.339 0.932 0.763 0.501–1.163 0.209
First cannulation time 0.862 0.582–1.276 0.458 0.930 0.585–1.477 0.758
Initial Qao500 mL/min 1.479 0.639–3.425 0.361 2.827 0.972–8.223 0.056
AntiPLT, antiplatelet agent; DM, diabetes mellitus; HTN, hypertension; PTA, percutaneous transluminal angioplasty; Qa, access ﬂow.
Figure 3. Survival in patients with an initial Qa4500 mL/minute
and those with an initial Qao500 mL/minute.
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patients with native AVF and previous angioplasty: of 69 patients
(23%) with stenosis, 53 underwent angioplasty, and 19 patients
had recurrent positive evaluations and underwent repeated
ﬁstulography. In our study, 27 patients (38.0%) underwent
angioplasty and 12 (44.4%) of those patients underwent repeated
angioplasty. However, these studies are not directly comparable,
because Tonelli and colleagues [23] used Canadian guidelines,
which, in patients with AFVs, calls for angiography when ﬁstula
ﬂow decreases to o500 mL/minute or drops 420% from base-
line and in patients with AVGs calls for angiography a when
blood ﬂow decreases to o650mL/minute or there is a drop of
420% from baseline. We used a modiﬁed version of the K/DOQI
and Canadian guidelines.
Our study has several limitations, including the small num-
ber of patients overall (selection bias) and the lack of randomi-
zation. It also did not perform preoperative mapping of vessels.
Because there is no standardized description for access and PTA
results in Korea, these outcomes may not deﬁnitively reﬂect
patency rates and access survival. Nevertheless, this prospective
study provided data on hemodialysis access in Korean patients.
In conclusion, an initial Qao500 mL/minute is a risk factor
for poor primary patency, while an initial Qao500 mL/minute
is not a risk factor for low cumulative patency or mortality.Conﬂict of interest
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